



A rewarding journey in the landscape between academia and industry

Senior lecturer Sara Mangsbo
Uppsala University
sara.mangsbo@farmbio.uu.se

Chief Innovation Officer Ultimovacs
Co-founder of Immuneed, Vivologica and
Strike pharma



UPPSALA
UNIVERSITET



UGSBR

Uppsala Graduate School of
Biomedical Research

2005-2006



UPPSALA
UNIVERSITET

Immunological Checkpoint Blockade and TLR Stimulation for Improved Cancer Therapy

SARA MANGSBO



PhD student

2006-2010



Thomas Tötterman



Angelica Loskog



First industry collaboration experience



2008-2015

CLINICAL CANCER RESEARCH

[Home](#) [About](#) [Articles](#) [For Authors](#) [Alerts](#) [News](#) [COVID-19](#) [Webinars](#) [Search Q](#)


Cancer Therapy: Preclinical

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity

Sara M. Mangsbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tötterman, and Peter Ellmark

Alligator Bioscience in Brief

- Clinical-stage biotech company
- Pioneers in tumor-directed immunotherapy
- 4 products in clinic/preclinic
- Strategic partnership with Janssen (J&J): USD 695 million + royalties
- Net cash position SEK 550 million



ALLIGATOR
bioscience



UPPSALA
UNIVERSITET

Postdoctor

2009-2011



Kees Melief



VR 3R grant

2012

ANSÖKAN: VETENSKAPSRÅDET - UTLYSNING MH SISTA DATUM 3 APRIL 2012 - STORA ANSÖKNINGSOMGÅNGEN 2012 - PROJEKT BIDRAG - MEDICIN OCH HÄLSA (MH) - FRITT

Projekttitel (svenska):

Ansökan: En avancerad immunologisk metod för att karakterisera terapeutiska antikroppar med hjälp av en liten mängd humant blod

Projektledare: Mangsbo, Sara

2012-02431

DIARIENUMMER

Beviljad

STATUS



UPPSALA
UNIVERSITET



Co-founder of Immuneed AB

2014

Immuneed secures SEK 4.3M in financing

MALIN OTMANI - SEPTEMBER 13, 2016



Immuneed secures SEK 4.3M in seed financing to further develop its immuno-oncology cancer vaccine candidate and grow its human whole-blood loop service for detection of acute immune related side effects of biopharmaceuticals.



International Immunopharmacology

journal homepage: www.elsevier.com/locate/intimp

Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics

Erika A.K. Fletcher^{a,b}, Mohamed Eltahir^b, Frida Lindqvist^a, Jonas Rieth^b, Gunilla Törnqvist^a, Justyna Leja-Jarblad^{a,b,1}, Sara M. Mangsbo^{a,c,*,1}

^a Immuneed AB, Dag Hammarskjölds väg 13a, Uppsala, Sweden

^b Department of Immunology Genetics and Pathology, Science for Life Laboratory, Uppsala University, Rudbeck Laboratory C11 Floor 2, Dag Hammarskjöldsväg 20, 751 85 Uppsala, Sweden

^c Department of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala University, BMC, Husargatan 3, 752 37 Uppsala, Sweden



UPPSALA
UNIVERSITET




UppsalaBIO- BIO-X program

2014

Tora Mangsbo is born July 2014

BIO-X[®] projektet: Utveckling av ett terapeutiskt vaccin mot cancer baserat på patientens egna immunsvar



Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses

Sara M. Mangsbo^{a,b,*}, Erika A.K. Fletcher^a, Wendy W.C. van Maren^c, Anke Redeker^c, Robert A. Cordfunke^c, Inken Dillmann^d, Jasper Dinkelaar^e, Kahina Ouchaou^e, Jeroen D.C. Codee^c, Gijs A. van der Marel^e, Peter Hoogerhout^f, Cornelis J.M. Melief^c, Ferry Ossendorp^c, Jan W. Drijfhout^c



This information is current as of September 16, 2021.

Formation of Immune Complexes with a Tetanus-Derived B Cell Epitope Boosts Human T Cell Responses to Covalently Linked Peptides in an Ex Vivo Blood Loop System

Erika A. K. Fletcher, Wendy van Maren, Robert Cordfunke, Jasper Dinkelaar, Jeroen D. C. Codee, Gijs van der Marel, Cornelis J. M. Melief, Ferry Ossendorp, Jan Wouter Drijfhout and Sara M. Mangsbo

J Immunol 2018; 201:87-97; Prepublished online 11 May 2018;
doi: 10.4049/jimmunol.1700911



UPPSALA
UNIVERSITET

Project Information

TIMCC

Grant agreement ID: 317445



Closed project

Start date

1 November 2012

End date


31 October 2016

Funded under
FP7-PEOPLE

Overall budget
€ 3 756 469

EU contribution
€ 3 756 469



Coordinated by
ACADEMISCH ZIEKENHUIS LEIDEN
 Netherlands

EU grant experience

2012-2016



Anna Dimberg



Sjeef Verbeek




UPPSALA
UNIVERSITET



Brand lead AZ

2015-2016



Jens Bjorheim

@DrJuhlin and @MjosbergL began their careers with SSMF's Large Grant. Maybe you're our future star. Read more and apply online: ssmf.se/for-forskare/s...



SSMF fellow

2016-2020

1,4 MSEK/year for 4 years



UPPSALA
UNIVERSITET

Immuno-oncology

BUL

2017-2021

Tenure track position





Foto: TT/Uppsala universitet

Uppsalaforskaren om Nobelpriset: "Revolutionerande"

UPPDATERAD 1 OKTOBER 2018 PUBLICERAD 1 OKTOBER 2018

James P. Allison och Tasuku Honjo får Nobelpriset i fysiologi eller medicin år 2018, för sin upptäckt av en ny cancerbehandling där man får immunförsvaret att angripa cancerceller.

– En fantastisk nyhet, säger Sara Mangsbo, forskare inom samma område vid Uppsala universitet.

James P Allison och Tasuku Honjo blir 2018 års vinnare av Nobelpriset i fysiologi eller medicin. De prisas för upptäckten av cancerbehandling genom hämmande av immunförsvarets bromsmekanismer.

Nobel prize in physiology and Medicine

2018

To the discovery of the role of CTLA-4 and PD-1 in regulating T cell activity and the therapeutic opportunity that comes from that discovery

Uppsalabo utsedd till Årets entreprenör

Uppsalabon – och cancerforskaren – Sara Mangsbo har utsetts till Årets entreprenör. "Det känns hedrande", säger hon.

19 JUNI 2019 15:28



Det är tidningen Veckans affärer som har utsett Sveriges 101 supertalanger under 40 år inom kategorierna samhällsbyggarna, karriäristerna, finansfolket och

Entrepreneur of the year

2019



UPPSALA
UNIVERSITET

Brain apple award

Innovation Prize to Sara Mangsbo

22 June 2020



Sara Mangsbo is this year's recipient of the Hjärnäpplet award.

Photograph: Mikael Wallerstedt

This year, the Uppsala University Innovation Prize for outstanding transfer of knowledge – the Hjärnäpple* – goes to Sara Mangsbo, Assistant Professor (docent) and Associate Senior Lecturer in Medical Science, and research leader at the Department of Pharmaceutical Biosciences.

2020



UPPSALA
UNIVERSITET

Co-founder Strike pharma AB

2020



Adaptable Drug Affinity Conjugate (ADAC)
targeting CD40,
Proof of Concept and Pharmaceutical profiling

Sara Mangsbo, PhD

Associate professor, Associate senior lecturer

Uppsala University

Co-founder STRIKE pharma AB



UPPSALA
UNIVERSITET

First patient dosed TENDU trial

2021

NORDIC LIFE SCIENCE NEWS

BUSINESS PHARMA MEDTECH BIOTECH SCIENCE CAREERS EVENTS PRESS ROOMS ABOUT US

First patient treated in Ultimovacs TENDU study

MALIN OTMANI • FEBRUARY 18, 2021



Ultimovacs has announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company's Tetanus-Epitope Targeting (TET)-platform.



UPPSALA
UNIVERSITET

Immuneed- global and expanding use of the blood loop system

The Immuneed logo is a circular arrangement of white and green dots on a dark green background. The navigation menu includes 'How it works', 'Services', 'Insight Hub', and 'About Us'.

Immuneed.

How it works Services Insight Hub About Us

A unique opportunity to study blood-drug interactions in real-time.

2021

International Immunopharmacology 90 (2021) 107226



Contents lists available at [ScienceDirect](#)

International Immunopharmacology

journal homepage: www.elsevier.com/locate/intimp

Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients

M. Eltahir^{a,b,1}, E. Fletcher^{c,1}, L. Dynesius^c, J.L. Jarblad^c, M. Lord^a, I. Laurén^a, M. Zekarias^a, X. Yu^d, M.S. Cragg^d, C. Hammarström^e, K.H. Levedahl^{f,g}, M. Höglund^f, G. Ullenhag^{b,h}, M. Mattsson^{b,f}, S.M. Mangsbo^{a,*}



UPPSALA
UNIVERSITET

Why both worlds?

Sweden is unique in its opportunity to realize your business idea and the support around you to facilitate that

Salary in the academia is low, but your innovative idea is owned by you, if you let it, it can flourish

Be interested and inclusive, you need that team

Build synergistic collaborations around you, can spur both grant opportunities and innovation

Find your drive and make your own journey



Thank you

